Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Paris and Tarrytown, NY, May 30, 2025. The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant reduction in moderate or severe acute exacerbations compared to placebo of 27% at week 52, a clinically meaningful benefit. The AERIFY-2 phase 3 study did not meet the same primary endpoint, although a benefit was seen earlier in the trial.